2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related

Interleukin Related

IL

Interleukin Related

Related Products

PDF 1.53 MB

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Isoform Specific Products:

Interleukin Related Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-181122
    MK169
    		Inhibitor
    MK169 is an IL-1β inhibitor. MK169 reduces LPS (HY-D1056)-induced IL-1β release in human aortic smooth muscle cells. MK169 is applicable to the research of cardiovascular inflammatory diseases such as atherosclerosis.
    MK169
  • HY-147141A
    HS-276 hydrochloride
    		Inhibitor
    HS-276 hydrochloride is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 hydrochloride shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 hydrochloride reduces the expression of TNF, IL-6, and IL-1β. HS-276 hydrochloride can be used for rheumatoid arthritis (RA) research.
    HS-276 hydrochloride
  • HY-N3421
    Koaburaside
    		Inhibitor
    Koaburaside is a cytoprotective and anti-inflammatory natural compound. Koaburaside shows antioxidant activity with an IC50 of 9.0 μM for DPPH-free radical scavenging assay. Koaburaside inhibits histamine release and expressions of IL-6 and TNF-α in human mast cells. Koaburaside also effectively inhibits influenza A neuraminidase.
    Koaburaside
  • HY-144373
    IL-17 modulator 6
    		Modulator
    IL-17 modulator 6 (compound 61) is a potent Interleukin 17 (IL-17) modulator (pIC50=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the research of inflammatory and autoimmune diseases.
    IL-17 modulator 6
  • HY-171837A
    t9,t11,c15-CLNA
    		Inhibitor
    t9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. t9,t11,c15-CLNA has the main activities of anti-inflammatory, antioxidant and improving intestinal barrier function. The regulatory mechanism of t9,t11,c15-CLNA includes upregulation of tight junction proteins, inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6) and activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be used in the study of inflammatory bowel diseases (such as colitis).
    t9,t11,c15-CLNA
  • HY-112448
    Lck-IN-6
    		Inhibitor
    Lck-IN-6 (Compound 12g) is a Lck inhibitor with an IC50 of 3 nM. Lck-IN-6 inhibits the production of IL-2. Lck-IN-6 can be used in the research of rheumatoid arthritis and inflammatory bowel disease.
    Lck-IN-6
  • HY-176535
    KB-0118
    		Inhibitor
    KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
    KB-0118
  • HY-183564
    RIPK1/RIPK3-PPI-IN-1
    		Inhibitor
    RIPK1/RIPK3-PPI-IN-1 is an orally active dual-target inhibitor of RIPK1/RIPK3, with a Kd value of 2.4 nM for RIPK1 and 24 nM for RIPK3. RIPK1/RIPK3-PPI-IN-1 inhibits the phosphorylation of RIPK1, RIPK3 and MLKL, thereby suppressing necroptosis. RIPK1/RIPK3-PPI-IN-1 restores body temperature, improves survival rate, and reduces IL-1β/IL-6 levels in serum and multiple organs of Mus musculus, thus alleviating TNF-α-induced systemic inflammatory response syndrome. RIPK1/RIPK3-PPI-IN-1 can be used in research related to systemic inflammatory response syndrome.
    RIPK1/RIPK3-PPI-IN-1
  • HY-115910
    Y13g
    		Inhibitor
    Y13g is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals.
    Y13g
  • HY-183283
    CAII-IN-15
    		Inhibitor
    CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma.
    CAII-IN-15
  • HY-172111
    EGFR-IN-144
    		Inhibitor
    EGFR-IN-144 (Compound 4B) exhibits inhibitory activities against EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). EGFR-IN-144 exhibits cytotoxicity in multiple cancer cell with GI50 of nanomolare levels. EGFR-IN-144 downregulates the expressions of mTOR, TNF-α, and IL-6, arrests the cell cycle at G1/S phase, and induces apoptosis.
    EGFR-IN-144
  • HY-P991438
    XmAb-662
    		Inhibitor
    XmAb-662 is a fusion protein targeting IL-12. XmAb-662 can be used in solid tumours research.
    XmAb-662
  • HY-181069
    Neuroprotective agent 16
    		Inhibitor
    Neuroprotective agent 16 is a blood-brain barrier-permeable neuroprotective agent. Neuroprotective agent 16 effectively scavenges DPPH and ABTS radicals, with IC50 values of 7.98 μM and 5.50 μM, respectively. Neuroprotective agent 16 exhibits anti-inflammatory, antioxidant, and DNA damage-reducing activities. Neuroprotective agent 16 can be used in research on diseases such as ischemic stroke.
    Neuroprotective agent 16
  • HY-P992028
    Anti-IL-1RA Antibody
    		Inhibitor
    Anti-IL-1RA Antibody is an anti-IL-1RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL-1RA Antibody
  • HY-P992375
    HuMax-IL15
    		Inhibitor
    HuMax-IL15 is a human IgG1 monoclonal antibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001).
    HuMax-IL15
  • HY-181484
    STING agonist-50
    		Activator
    STING agonist-50 is an orally active STING agonist with an IC50 of 3.457 μM. STING agonist-50 activates the STING signaling pathway and promotes the phosphorylation of downstream TBK1 and IRF3. STING agonist-50 induces the expression of IFN-β, CXCL10 and IL-6. STING agonist-50 inhibits tumor growth in syngeneic mouse models. STING agonist-50 can be used for the research of colorectal cancer.
    STING agonist-50
  • HY-182610
    ISP-VT
    		Inhibitor
    ISP-VT (Isopropyl vanillate) is a COX-2 inhibitor. ISP-VT exhibits anti-inflammatory, antipyretic and immunomodulatory activities. ISP-VT reduces neutrophil migration and the release of inflammatory factors. ISP-VT can be used for the research of inflammatory and immune diseases and other conditions.
    ISP-VT
  • HY-175655
    BChE/p38-α MAPK-IN-1
    		Inhibitor
    BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation.
    BChE/p38-α MAPK-IN-1
  • HY-183313
    IAV-IN-5
    		Inhibitor
    IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection.
    IAV-IN-5
  • HY-RS06713
    IL1A Human Pre-designed siRNA Set A
    		Inhibitor

    IL1A Human Pre-designed siRNA Set A contains three designed siRNAs for IL1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    IL1A Human Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Interleukin Related Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.